2(N-乙基氨基甲酰羟基甲基)呋喃 | 63833-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 2(N-乙基氨基甲酰羟基甲基)呋喃
• 英文名称: FURFURYL ALCOHOL, alpha-(N-ETHYLCARBAMOYL)-
• 英文别名: N-ethyl-2-(furan-2-yl)-2-hydroxyacetamide
• CAS: 63833-90-9
• 化学式: C₈H₁₁NO₃
• mdl: MFCD01725764
• 分子量: 169.18
• InChiKey: IKWNXBMYMBMNKP-UHFFFAOYSA-N

物化性质

• 沸点：
  298.46°C (rough estimate)
• 密度：
  1.2435 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  62.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Multi-stage stem cell carcinogenesis
  申请人：Krtolica Ana

  公开号：US20100162416A1

  公开（公告）日：2010-06-24

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.
• [EN] MULTI-STAGE STEM CELL CARCINOGENESIS<br/>[FR] CARCINOGENESE DE CELLULES SOUCHES MULTIETAPES
  申请人：STEMLIFELINE INC

  公开号：WO2010037134A2

  公开（公告）日：2010-04-01

  The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.